Walter Jentzen YOU? Author Swipe

Last 10y

Quantitative evaluation of 123I-MIBG imaging in patients with myocarditis: impairment of cardiac neuronal function revisited Open

Lukas Kessler, Stephan Settelmeier, Kim M. Pabst, Tuğçe Telli, Zohreh Varasteh , et al. · 2025

Background 123 I-MIBG has been shown to visualize impaired cardiac neuronal function, but data of this imaging modality in patients with acute myocarditis are scarce. Nonetheless, an association with reduced cardiac function has been obser…

Detection and quantification of small and low‐uptake lesions for differentiated thyroid carcinoma using non‐time‐of‐flight iodine‐124 PET/MRI Open

Maike E. Lindemann, Walter Jentzen, David Kersting, Pedro Fragoso Costa, Alina Küper , et al. · 2024

Background 124‐iodine ( 124 I) is used for positron emission tomography (PET) diagnostics and therapy planning in patients with differentiated thyroid cancer (DTC). Small lesion sizes (<10 mm) and low 124 I uptake are challenging condition…

PET quantification performance of the oversize-volume-of-interest approach in the context of tumour dosimetry in radionuclide therapy planning Open

N Hammersen, Walter Jentzen, Florian Stawitzki, Ken Herrmann, David Kersting , et al. · 2024

Objective. The partial-volume effect (PVE) is an important factor impairing tumour quantification in molecular imaging. The commonly used contour-volume-of-interest (contour-VOI) approach to correct for this effect employs phantom-based re…

Biodistribution and radiation dosimetry of 124I-mIBG in adult patients with neural crest tumours and extrapolation to paediatric models Open

Alexandros Moraitis, Walter Jentzen, Gloria Reiter, Jochen Schmitz, Thorsten Pöppel , et al. · 2024

Aim Positron emission tomography (PET) using 124 I-mIBG has been established for imaging and pretherapeutic dosimetry. Here, we report the first systematic analysis of the biodistribution and radiation dosimetry of 124 I-mIBG in patients w…

Renal and Multiorgan Safety of<sup>177</sup>Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer in the VISION Dosimetry Substudy Open

Ken Herrmann, Kambiz Rahbar, Matthias Eiber, Richard Sparks, Nicholas Baca , et al. · 2023

In the VISION trial, [¹⁷⁷Lu]Lu-PSMA-617 (¹⁷⁷Lu-PSMA-617) plus protocol-permitted standard of care significantly improved overall survival and radiographic progression-free survival compared with standard of care alone…

Supplementary Data from Enhancing Radioiodine Incorporation into Radioiodine-Refractory Thyroid Cancer with MAPK Inhibition (ERRITI): A Single-Center Prospective Two-Arm Study Open

Manuel Weber, David Kersting, Burkhard Riemann, Tim Brandenburg, Dagmar Führer‐Sakel , et al. · 2023

Supplementary Data from Enhancing Radioiodine Incorporation into Radioiodine-Refractory Thyroid Cancer with MAPK Inhibition (ERRITI): A Single-Center Prospective Two-Arm Study

Data from Enhancing Radioiodine Incorporation into Radioiodine-Refractory Thyroid Cancer with MAPK Inhibition (ERRITI): A Single-Center Prospective Two-Arm Study Open

Manuel Weber, David Kersting, Burkhard Riemann, Tim Brandenburg, Dagmar Führer‐Sakel , et al. · 2023

Purpose:Restoration of iodine incorporation (redifferentiation) by MAPK inhibition was achieved in previously radioiodine-refractory, unresectable thyroid carcinoma (RR-TC). However, results were unsatisfactory in BRAF^V600E-muta…

Supplementary Figure from Enhancing Radioiodine Incorporation into Radioiodine-Refractory Thyroid Cancer with MAPK Inhibition (ERRITI): A Single-Center Prospective Two-Arm Study Open

Manuel Weber, David Kersting, Burkhard Riemann, Tim Brandenburg, Dagmar Führer‐Sakel , et al. · 2023

Supplementary Figure from Enhancing Radioiodine Incorporation into Radioiodine-Refractory Thyroid Cancer with MAPK Inhibition (ERRITI): A Single-Center Prospective Two-Arm Study

Supplementary Figure from Enhancing Radioiodine Incorporation into Radioiodine-Refractory Thyroid Cancer with MAPK Inhibition (ERRITI): A Single-Center Prospective Two-Arm Study Open

Manuel Weber, David Kersting, Burkhard Riemann, Tim Brandenburg, Dagmar Führer‐Sakel , et al. · 2023

Supplementary Figure from Enhancing Radioiodine Incorporation into Radioiodine-Refractory Thyroid Cancer with MAPK Inhibition (ERRITI): A Single-Center Prospective Two-Arm Study

Supplementary Data from Enhancing Radioiodine Incorporation into Radioiodine-Refractory Thyroid Cancer with MAPK Inhibition (ERRITI): A Single-Center Prospective Two-Arm Study Open

Manuel Weber, David Kersting, Burkhard Riemann, Tim Brandenburg, Dagmar Führer‐Sakel , et al. · 2023

Supplementary Data from Enhancing Radioiodine Incorporation into Radioiodine-Refractory Thyroid Cancer with MAPK Inhibition (ERRITI): A Single-Center Prospective Two-Arm Study

Data from Enhancing Radioiodine Incorporation into Radioiodine-Refractory Thyroid Cancer with MAPK Inhibition (ERRITI): A Single-Center Prospective Two-Arm Study Open

Manuel Weber, David Kersting, Burkhard Riemann, Tim Brandenburg, Dagmar Führer‐Sakel , et al. · 2023

Purpose:Restoration of iodine incorporation (redifferentiation) by MAPK inhibition was achieved in previously radioiodine-refractory, unresectable thyroid carcinoma (RR-TC). However, results were unsatisfactory in BRAF^V600E-muta…

Supplementary Data from Enhancing Radioiodine Incorporation into Radioiodine-Refractory Thyroid Cancer with MAPK Inhibition (ERRITI): A Single-Center Prospective Two-Arm Study Open

Manuel Weber, David Kersting, Burkhard Riemann, Tim Brandenburg, Dagmar Führer‐Sakel , et al. · 2023

Supplementary Data from Enhancing Radioiodine Incorporation into Radioiodine-Refractory Thyroid Cancer with MAPK Inhibition (ERRITI): A Single-Center Prospective Two-Arm Study

Supplementary Figure from Enhancing Radioiodine Incorporation into Radioiodine-Refractory Thyroid Cancer with MAPK Inhibition (ERRITI): A Single-Center Prospective Two-Arm Study Open

Manuel Weber, David Kersting, Burkhard Riemann, Tim Brandenburg, Dagmar Führer‐Sakel , et al. · 2023

Supplementary Figure from Enhancing Radioiodine Incorporation into Radioiodine-Refractory Thyroid Cancer with MAPK Inhibition (ERRITI): A Single-Center Prospective Two-Arm Study

Supplementary Figure from Enhancing Radioiodine Incorporation into Radioiodine-Refractory Thyroid Cancer with MAPK Inhibition (ERRITI): A Single-Center Prospective Two-Arm Study Open

Manuel Weber, David Kersting, Burkhard Riemann, Tim Brandenburg, Dagmar Führer‐Sakel , et al. · 2023

Supplementary Figure from Enhancing Radioiodine Incorporation into Radioiodine-Refractory Thyroid Cancer with MAPK Inhibition (ERRITI): A Single-Center Prospective Two-Arm Study

Supplementary Data from Enhancing Radioiodine Incorporation into Radioiodine-Refractory Thyroid Cancer with MAPK Inhibition (ERRITI): A Single-Center Prospective Two-Arm Study Open

Manuel Weber, David Kersting, Burkhard Riemann, Tim Brandenburg, Dagmar Führer‐Sakel , et al. · 2023

Supplementary Data from Enhancing Radioiodine Incorporation into Radioiodine-Refractory Thyroid Cancer with MAPK Inhibition (ERRITI): A Single-Center Prospective Two-Arm Study

Supplementary Figure from Enhancing Radioiodine Incorporation into Radioiodine-Refractory Thyroid Cancer with MAPK Inhibition (ERRITI): A Single-Center Prospective Two-Arm Study Open

Manuel Weber, David Kersting, Burkhard Riemann, Tim Brandenburg, Dagmar Führer‐Sakel , et al. · 2023

Supplementary Figure from Enhancing Radioiodine Incorporation into Radioiodine-Refractory Thyroid Cancer with MAPK Inhibition (ERRITI): A Single-Center Prospective Two-Arm Study

Supplementary Figure from Enhancing Radioiodine Incorporation into Radioiodine-Refractory Thyroid Cancer with MAPK Inhibition (ERRITI): A Single-Center Prospective Two-Arm Study Open

Manuel Weber, David Kersting, Burkhard Riemann, Tim Brandenburg, Dagmar Führer‐Sakel , et al. · 2023

Supplementary Figure from Enhancing Radioiodine Incorporation into Radioiodine-Refractory Thyroid Cancer with MAPK Inhibition (ERRITI): A Single-Center Prospective Two-Arm Study

Efficacy and Safety of<sup>124</sup>I-MIBG Dosimetry-Guided High-Activity<sup>131</sup>I-MIBG Therapy of Advanced Pheochromocytoma or Neuroblastoma Open

Ines Maríc, Manuel Weber, Andre Prochnow, Jochen Schmitz, Nicole Unger , et al. · 2023

We aim to evaluate the efficacy and safety of ¹²⁴I-metaiodobenzylguanidine (MIBG) dosimetry-guided high-activity ¹³¹I-MIBG therapy of advanced pheochromocytoma or neuroblastoma. Methods: Fourteen patients with …

Lesion Quantification Accuracy of Digital<sup>90</sup>Y PET Imaging in the Context of Dosimetry in Systemic Fibroblast Activation Protein Inhibitor Radionuclide Therapy Open

David Kersting, Walter Jentzen, Daniel Jeromin, Ilektra-Antonia Mavroeidi, Maurizio Conti , et al. · 2022

Therapy with ⁹⁰Y-labeled fibroblast activation protein inhibitors (⁹⁰Y-FAPIs) was recently introduced as a novel treatment concept for patients with solid tumors. Lesion and organ-at-risk dosimetry is part of assessin…

Phantom-based acquisition time and image reconstruction parameter optimisation for oncologic FDG PET/CT examinations using a digital system Open

Pedro Fragoso Costa, Walter Jentzen, Alissa Brahmer, Ilektra-Antonia Mavroeidi, Fadi Zarrad , et al. · 2022

Enhancing Radioiodine Incorporation into Radioiodine-Refractory Thyroid Cancer with MAPK Inhibition (ERRITI): A Single-Center Prospective Two-Arm Study Open

Manuel Weber, David Kersting, Burkhard Riemann, Tim Brandenburg, Dagmar Führer‐Sakel , et al. · 2022

Purpose: Restoration of iodine incorporation (redifferentiation) by MAPK inhibition was achieved in previously radioiodine-refractory, unresectable thyroid carcinoma (RR-TC). However, results were unsatisfactory in BRAFV600E-mutant (BRAF-M…

Quantitative 99mTc-DPD-SPECT/CT assessment of cardiac amyloidosis Open

Lukas Kessler, Pedro Fragoso Costa, David Kersting, Walter Jentzen, Manuel Weber , et al. · 2022

INTRODUCTION: Transthyretin (ATTR) amyloidosis is responsible for the majority of cardiac amyloidosis (CA) cases and can be reliably diagnosed with bone scintigraphy and the visual Perugini score. We aimed to implement a quantification met…

Implementation of a Spatially-Variant and Tissue-Dependent Positron Range Correction for PET/CT Imaging Open

Hunor Kertész, Thomas Beyer, Vladimir Panin, Walter Jentzen, Jacobo Cal-González , et al. · 2022

Aim To develop and evaluate a new approach for spatially variant and tissue-dependent positron range (PR) correction (PRC) during the iterative PET image reconstruction. Materials and Methods The PR distributions of three radionuclides ( 1…

Preliminary results of the experimental cross sections of the long-lived <i>β</i><sup>+</sup> emitters of interest in PET range verification in proton therapy at clinical energies Open

T. Rodríguez-González, C. Guerrero, Claus Maximilian Bäcker, Christian Bäumer, Walter Jentzen , et al. · 2022

In proton therapy, offline PET range verification requires a comparison of the measured and expected β + activity distributions produced by the proton field in the body, looking at the the long-lived β + emitters. The reliability of the ex…

[68Ga]Ga-PSMA-11 PET imaging as a predictor for absorbed doses in organs at risk and small lesions in [177Lu]Lu-PSMA-617 treatment Open

Steffie M. B. Peters, Regina Hofferber, Bastiaan M. Privé, Maarten de Bakker, Martin Gotthardt , et al. · 2021

Diagnostic Performance of<sup>124</sup>I-Metaiodobenzylguanidine PET/CT in Patients with Pheochromocytoma Open

Manuel Weber, Jochen Schmitz, Ines Maríc, Kim M. Pabst, Lale Umutlu , et al. · 2021

^123/131I-metaiodobenzylguanidine (MIBG) scintigraphy has shown a high specificity for imaging pheochromocytoma and paraganglioma, but with low sensitivity because of low spatial resolution. ¹²⁴I-MIBG PET may be able t…

Silicon-photomultiplier-based PET/CT reduces the minimum detectable activity of iodine-124 Open

David Kersting, Walter Jentzen, Pedro Fragoso Costa, Miriam Sraieb, Patrick Sandach , et al. · 2021

The radioiodine isotope pair 124 I/ 131 I is used in a theranostic approach for patient-specific treatment of differentiated thyroid cancer. Lesion detectability is notably higher for 124 I PET (positron emission tomography) than for 131 I…

Intra-therapeutic dosimetry of [177Lu]Lu-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer patients and correlation with treatment outcome Open

Steffie M. B. Peters, Bastiaan M. Privé, Maarten de Bakker, Frank de Lange, Walter Jentzen , et al. · 2021

Prognostic Value of Postinduction Chemotherapy Volumetric PET/CT Parameters for Stage IIIA or IIIB Non–Small Cell Lung Cancer Patients Receiving Definitive Chemoradiotherapy Open

Maja Guberina, Christoph Pöttgen, Martin Metzenmacher, Marcel Wiesweg, Martin Schüler , et al. · 2021

Purpose/Objective(s): The aim of this follow-up analysis of the ESPATUE phase-3 trial was to explore the prognostic value of post-induction chemotherapy PET metrics in patients with stage III non-small cell lung cancer (NSCLC) who w…

Evaluation of [68Ga]Ga-PSMA PET/CT images acquired with a reduced scan time duration in prostate cancer patients using the digital biograph vision Open

Manuel Weber, Walter Jentzen, Regina Hofferber, Ken Herrmann, Wolfgang P. Fendler , et al. · 2021

Fetching topic information...